Inhibition of the pseudokinase MLKL alters extracellular vesicle release and reduces tumor growth in glioblastoma
Gwennan André-Grégoire,
Clément Maghe,
Tiphaine Douanne,
Sara Rosińska,
Fiorella Spinelli,
An Thys,
Kilian Trillet,
Kathryn A. Jacobs,
Cyndie Ballu,
Aurélien Dupont,
Anne-Marie Lyne,
Florence M.G. Cavalli,
Ignacio Busnelli,
Vincent Hyenne,
Jacky G. Goetz,
Nicolas Bidère,
Julie Gavard
Affiliations
Gwennan André-Grégoire
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Institut de Cancérologie de l’Ouest (ICO), Saint-Herblain, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Clément Maghe
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Tiphaine Douanne
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Sara Rosińska
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Fiorella Spinelli
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
An Thys
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Kilian Trillet
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Kathryn A. Jacobs
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Cyndie Ballu
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Institut Curie, PSL Research University, Paris, France; Inserm, U900, Paris, France; MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Paris, France
Florence M.G. Cavalli
Institut Curie, PSL Research University, Paris, France; Inserm, U900, Paris, France; MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Paris, France
Ignacio Busnelli
Equipe Labellisée Ligue Contre le Cancer, Paris, France; INSERM UMR_S1109, Tumor Biomechanics, Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
Vincent Hyenne
Equipe Labellisée Ligue Contre le Cancer, Paris, France; INSERM UMR_S1109, Tumor Biomechanics, Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; CNRS SNC5055, Strasbourg, France
Jacky G. Goetz
Equipe Labellisée Ligue Contre le Cancer, Paris, France; INSERM UMR_S1109, Tumor Biomechanics, Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; CNRS SNC5055, Strasbourg, France
Nicolas Bidère
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France
Julie Gavard
Team SOAP, CRCI2NA, Nantes Université, Inserm, CNRS, Université d’Angers, Nantes, France; Institut de Cancérologie de l’Ouest (ICO), Saint-Herblain, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France; Corresponding author
Summary: Extracellular vesicles (EVs) are lipid-based nanosized particles that convey biological material from donor to recipient cells. EVs play key roles in glioblastoma progression because glioblastoma stem-like cells (GSCs) release pro-oncogenic, pro-angiogenic, and pro-inflammatory EVs. However, the molecular basis of EV release remains poorly understood. Here, we report the identification of the pseudokinase MLKL, a crucial effector of cell death by necroptosis, as a regulator of the constitutive secretion of EVs in GSCs. We find that genetic, protein, and pharmacological targeting of MLKL alters intracellular trafficking and EV release, and reduces GSC expansion. Nevertheless, this function ascribed to MLKL appears independent of its role during necroptosis. In vivo, pharmacological inhibition of MLKL reduces the tumor burden and the level of plasmatic EVs. This work highlights the necroptosis-independent role of MLKL in vesicle release and suggests that interfering with EVs is a promising therapeutic option to sensitize glioblastoma cells.